News

The study, which represents the first human trial of hcMSCs for AD, found the treatment was associated with “significant” improvements in symptoms.

Matthew Zirwas, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis involving intense itch and severe hand dermatitis.

Some patients may be looking for alternatives to BPO, questioning its safety.

Keep up with the latest headlines in dermatology from the past week, including the appointment of the Canadian Dermatology Association's new president, a program aimed at supporting diverse, aspiring dermatologists, and more.

In case you missed it, this week we had news about the FDA's approval of biosimilar ustekinumab-ttwe, addressing acne scarring concerns, the intersection of permanent makeup and dermatology, and more.

Phase 3 trials found the treatment demonstrated efficacy as early as week 1 of treatment and sustained this response through week 52.

Adewole Adamson, MD, MPP, discusses the Environmental Working Group's 2024 Guide to Sunscreens and what clinicians should discuss with patients who express concerns with the headlines stemming from the report.

Dermatology Times' Summer Editor in Chief, Shanna Miranti, MPAS, PA-C, shares how she has learned to be happy, stay humble, and be brilliant in her more than 22 years in dermatology.

Shahriari spoke about the importance of comprehensive care, collaborating with other specialists, and addressing psychosocial impact.

The first issue of Dermatology Times was published in 1979 to offer clinical insights into a growing health care specialty.

A recent study offers a comprehensive analysis of practice patterns and patient characteristics in different clinical settings.

As many as 76.5% of participants could not name any psychodermatology resources, while only 58.8% were definitively interested in training on the topic.

Iain Stuart, PhD, discusses VYN202's status and potential in psoriasis and immuno-inflammatory diseases.

Walter Liszewski, MD, shares insights into discrepancies between permanent makeup and decorative tattoos and which patients may benefit from permanent makeup.

Explore evidence-based clinical recommendations for fireworks burns, chlorine irritation, and more.

A recent study found that subjects reported an improvement in elasticity and firmness, with decreased fine lines and wrinkles after 8 and 12 weeks of use.

Biofrontera's red light source is approved for use in combination with aminolevulinic acid hydrochloride (Ameluz) topical gel, 10%.

Recent research and conversations shared at the National Eczema Association expo tackled the link between patient well-being and eczema.

Adopting diversity management is not just a choice but a pressing need in the evolving health care landscape.

A new report delves into the case of a 35-year-old man with ARPC and why dupilumab was utilized for treatment.

James Song, MD, shares a comprehensive guide to what is new, what is now, and what is next in AD treatment.

With the latest advancements in dermatology, there is a great range of treatments available to address the various types of acne scarring.

A recent review found success from a 3-component, simplified habit reversal therapy implemented by dermatologists for BFRBs.

Pyzchiva will be commercialized by Sandoz in the United States.

A recent study demonstrated the benefits and limitations of PatientsLikeMe for patients with atopic dermatitis and other skin conditions.

Dermatology Times asked our readers to share what conferences they are looking forward to in the third quarter of 2024.

Keep up with the latest headlines in dermatology from the past week, including application of AI in dermatology, exposure to forever chemicals through the skin, and more.

In case you missed it, this week we had news about sarecycline's efficacy in periorificial dermatitis, Health Canada's authorization of lebrikizumab for AD, the FDA's investigational new drug clearance of ENS-002 for AD, and more.

Researchers found that the hemp derivative addressed multiple facets of acne pathophysiology and improved acne scarring overall.

Risankizumab outperformed other biologics in real-world psoriasis treatment, achieving higher PASI 90/100 rates and patient satisfaction.